PMB-CT01

PMB-CT01 is a first-in-class, autologous chimeric antigen receptor (CAR) T cell therapy that targets the B-cell activating factor receptor (BAFF-R), a member of the tumor necrosis factor (TNF) receptor superfamily expressed almost exclusively on B cells. The therapy is designed to treat relapsed and refractory B-cell malignancies—including B-cell acute lymphoblastic leukemia (B-ALL) and various subtypes of B-cell lymphomas—especially in patients who are ineligible for or have failed prior CD19-targeted therapies[1][3][4]. The mechanism involves genetically engineering a patient’s own T cells to express an anti-BAFF-R single-chain variable fragment (scFv), combined with second-generation signaling domains containing CD3ζ and 4-1BB. This enables the modified T cells to recognize and kill malignant B cells expressing BAFF-R[3][6]. Preclinical studies demonstrated potent activity against human lymphomas and leukemias both in vitro and in animal models. Early clinical trials have shown promising safety profiles, high response rates, durable remissions, manageable toxicities (mainly low-grade cytokine release syndrome), and potential advantages over existing CD19 CAR-T therapies due to reduced risk of antigen escape[2][5][7].

Other names

BAFFR-CAR T cellBAFF-R CAR T cellBAFFR(EQ)BBζ/EGFRt+ CAR T Cells